No translate

Đặng Mai Phương; Nguyễn Văn Tuận; Nguyễn Thanh Bình

doi:10.62511/vjn.51.2026.118

Home

Articles Issue: Số 51 - 2026 Bệnh thần kinh - cơ

No translate

Published: October 24, 2026

Lượt đọc: 11

10.62511/vjn.51.2026.118

Abstract

No translate

Keywords

No translate

References

Gilhus NE. Myasthenia Gravis. N Engl J Med 2016;375(26):2570-2581. doi:10.1056/NEJMra1602678\

DOI: doi.org/10.1056/nejmra1602678

Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 2014;21(5):687-693. doi:10.1111/ene.12359\

DOI: doi.org/10.1111/ene.12359

Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124\

DOI: doi.org/10.1212/wnl.0000000000011124

Priola AM, Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol 2014;69(5):e230-245. doi:10.1016/j.crad.2014.01.005\

DOI: doi.org/10.1016/j.crad.2014.01.005

Murai H. The Japanese Clinical Guidelines 2022 for Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: An Overview. Brain Nerve 2024;76(1):7-12. doi:10.11477/mf.1416202551\

DOI: doi.org/10.11477/mf.1416202551

Nguyễn Hữu Công. Chẩn đoán và điều trị các bệnh thần kinh cơ thường gặp. Hà Nội: Nhà xuất bản Y học; 2018. tr. 142-158.\

Shuey NH. Ocular myasthenia gravis: a review and practical guide for clinicians. Clin Exp Optom 2022;105(2):205-213. doi:10.1080/08164622.2022.2029683\

DOI: doi.org/10.1080/08164622.2022.2029683

Fang CEH, Bokre D, Wong SH. Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: A Systematic Review and Meta-analysis. Neurology 2023;101(16):e1594-e1605. doi:10.1212/WNL.0000000000207642\

DOI: doi.org/10.1212/wnl.0000000000207642

Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55(1):16-23. doi:10.1212/wnl.55.1.16\

DOI: doi.org/10.1212/wnl.55.1.16

10.

Muppidi S, Wolfe GI, Conaway M, Burns TM, MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve 2011;44(5):727-731. doi:10.1002/mus.22140

DOI: doi.org/10.1002/mus.22140